The extent of lymphadenectomy in gastric cancer (GC) surgery has been for long time a matter of debate. Randomized trials performed in the West reported worse results of D2 dissection, in terms of postoperative complications and long-term survival benefit, than Eastern series and observational studies from specialized Western centers. However, long-term re-evaluation of such trials and in depth-analysis of other experiences demonstrated the potential benefit of D2 in reducing the probability of cancer-related death and the safety of this procedure when avoiding unnecessary spleno-pancreatectomy and in centers with ad adequate surgical volume. Nowadays, the D2 is considered the standard treatment in most guidelines all over the world. More limited procedures (D1, D1 plus) may be adequate in selected cases, and more extended dissections (D2 plus) could be indicated in advanced forms with high risk of metastases to distant nodes, but in specialized centers or in the setting of clinical studies. The integration with neoadjuvant therapies and multimodality approach could offer a chance of cure in groups of patients with poor results when approached with standard treatment.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Lymphadenectomy: State of the art|
|Rivista:||TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY|
|Citazione:||Marrelli, D., DE FRANCO, L.G., Iudici, L., Polom, K.R., & Roviello, F. (2017). Lymphadenectomy: State of the art. TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2017(JAN), 3-3.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: